Edgewise Therapeutics Announces Positive Topline Results From EDG-5506 Phase 1b Trial in Adults With Becker
Edgewise Therapeutics today announced positive topline results from the Phase 1b clinical trial of EDG-5506 in Becker muscular dystrophy. EDG-5506 is an oral small molecule muscle stabilizer which seeks to protect the muscle from injuries…Learn More